New Day Diagnostics Company Profile

Background

Overview

New Day Diagnostics is a diagnostic healthcare company headquartered in Knoxville, Tennessee, specializing in the development and commercialization of innovative diagnostic solutions aimed at improving patient outcomes and reducing healthcare costs. The company operates as a Contract Research Organization (CRO) and maintains an ISO 13485:2016 and CLIA-certified in vitro diagnostics laboratory. Their primary focus areas include oncology, gastrointestinal diseases, infectious diseases, and women's health. New Day Diagnostics is committed to delivering accessible, high-quality diagnostics through a range of services, from biomarker discovery to product launch.

Mission and Vision

The mission of New Day Diagnostics is to empower individuals with innovative, accessible diagnostics that lead to improved health outcomes. Their vision is to transform healthcare by providing cost-effective, non-invasive diagnostic tests that facilitate early disease detection and monitoring, thereby enhancing patient care and reducing the burden on healthcare systems.

Industry Significance

In the rapidly evolving diagnostics industry, New Day Diagnostics stands out for its comprehensive approach, integrating assay design, clinical performance evaluation, and analytical performance evaluation. This vertical integration enables the company to expedite the development and commercialization of diagnostic tests, positioning it as a significant player in the field.

Key Strategic Focus

Core Objectives

Innovation in Diagnostics: Develop and commercialize novel diagnostic tests that address unmet medical needs.

Accessibility: Ensure that diagnostic solutions are affordable and easy to use, facilitating widespread adoption.

Early Detection: Focus on early disease detection to improve patient outcomes and reduce healthcare costs.

Areas of Specialization

Oncology: Development of diagnostic tests for early detection of various cancers.

Gastrointestinal Diseases: Innovative diagnostics for conditions affecting the digestive system.

Infectious Diseases: Rapid and accurate tests for detecting infectious agents.

Women's Health: Diagnostics tailored to address health concerns specific to women.

Key Technologies Utilized

Molecular Diagnostics: Utilizing DNA and RNA analysis for precise disease detection.

Multiplex Assays: Simultaneous detection of multiple biomarkers to enhance diagnostic efficiency.

Point-of-Care Testing: Development of tests that provide immediate results, improving patient management.

Primary Markets Targeted

Healthcare Providers: Hospitals, clinics, and laboratories seeking reliable diagnostic solutions.

Patients: Individuals requiring accessible and non-invasive diagnostic tests.

Regulatory and Research Organizations: Collaborations for clinical trials and regulatory approvals.

Financials and Funding

Funding History

New Day Diagnostics has raised a total of $200,000 over four funding rounds, with the latest round completed on May 13, 2013.

Recent Funding Rounds

May 13, 2013: Raised $200,000.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Utilization of Capital

The funds have been utilized to support the development of diagnostic tests, enhance laboratory capabilities, and expand research and development efforts.

Pipeline Development

Key Pipeline Candidates

ColoHealth™: A blood test for the early detection of colorectal cancer, developed through the acquisition of assets from Epigenomics AG.

Stages of Development

Clinical Trials: Ongoing studies to validate the efficacy and safety of diagnostic tests.

Regulatory Approvals: Pursuing FDA approvals for various diagnostic products.

Target Conditions

Colorectal Cancer: Early detection to improve survival rates.

Celiac Disease: Non-invasive testing for gluten sensitivity.

Infectious Diseases: Rapid detection of pathogens.

Anticipated Milestones

FDA Approval: Expected for ColoHealth™ and other diagnostic tests in the near future.

Market Launch: Planned introduction of tests to healthcare providers and consumers.

Technological Platform and Innovation

Proprietary Technologies

Methylated DNA Detection: Utilizing proprietary biomarker technology for the detection of methylated DNA, enhancing the sensitivity and specificity of cancer diagnostics.

Significant Scientific Methods

Assays: Development of multiplex assays for simultaneous detection of multiple biomarkers.

Clinical Performance Evaluation: Comprehensive studies to assess the effectiveness and safety of diagnostic tests.

Leadership Team

Eric Mayer: President and CEO of New Day Diagnostics, leading the company's strategic direction and operations.

Mark Boyd: Sales and Marketing Director, responsible for driving the company's sales strategies and market presence.

Leadership Changes

No significant leadership changes have been reported recently.

Competitor Profile

Market Insights and Dynamics

The diagnostic testing market is experiencing significant growth, driven by advancements in molecular diagnostics, increasing prevalence of chronic diseases, and a growing emphasis on early disease detection. The market is characterized by rapid technological innovations and a shift towards personalized medicine.

Competitor Analysis

Quest Diagnostics: A leading provider of diagnostic information services, offering a broad range of tests and services.

Cepheid: Specializes in molecular diagnostics, providing rapid and accurate testing solutions.

QuidelOrtho: Focuses on diagnostic healthcare products, including tests for infectious diseases and other conditions.

Strategic Collaborations and Partnerships

Hepion Pharmaceuticals: Entered into a binding letter of intent to commercialize diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and hepatocellular carcinoma.

SehaMed Global Ltd: Partnered to launch ColoHealth™ in the Middle East, expanding market reach.

Lynsight Ltd: Announced a strategic partnership to advance DiagMMR clinical studies in the United States.

Operational Insights

New Day Diagnostics differentiates itself through its vertically integrated approach, combining assay design, clinical trial management, and commercialization capabilities. This integration allows for efficient development and deployment of diagnostic tests, providing a competitive edge in the market.

Strategic Opportunities and Future Directions